This HTML5 document contains 31 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/mesh/concept/
n8http://linked.opendata.cz/resource/drugbank/company/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00110/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
n22http://linked.opendata.cz/resource/drugbank/drug/DB00110/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n20http://linked.opendata.cz/resource/drugbank/patent/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n12http://www.drugs.com/cdi/
n24http://linked.opendata.cz/resource/drugbank/property/
n13http://www.rxlist.com/cgi/generic2/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00110/identifier/wikipedia/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00110/identifier/pharmgkb/
n21http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00110
rdf:type
n3:Drug
n3:description
Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)
n3:dosage
n4:271B4600-363D-11E5-9242-09173F13E4C5 n4:271B45FD-363D-11E5-9242-09173F13E4C5 n4:271B45FE-363D-11E5-9242-09173F13E4C5 n4:271B45FF-363D-11E5-9242-09173F13E4C5
n3:group
approved investigational
n3:halfLife
18-20 days (in adults)
n3:indication
For prophylaxis of respiratory diseases casued by respiratory syncytial virus.
owl:sameAs
n6:DB00110 n19:DB00110
dcterms:title
Palivizumab
adms:identifier
n15:PA164748781 n16:Palivizumab n22:60574-4114-1 n23:DB00110
n3:mechanismOfAction
Palivizumab binds to the fusion glycoprotein of RSV. This prevents its binding and uptake by host cellular receptors.
n3:packager
n8:271B45FB-363D-11E5-9242-09173F13E4C5 n8:271B45FC-363D-11E5-9242-09173F13E4C5
n3:patent
n20:2197684
n3:synonym
Synagis anti-RSV
n9:hasAHFSCode
n10:08-18-24
n17:hasConcept
n18:M0288015
foaf:page
n12:palivizumab.html n13:palivizumab.htm
n9:hasATCCode
n21:J06BB16
n3:casRegistryNumber
188039-54-5
n3:category
n3:Melting-Point
n24:271B4601-363D-11E5-9242-09173F13E4C5